Berkshire Asset Management LLC PA Sells 4,511 Shares of Eli Lilly And Co (LLY)

Berkshire Asset Management LLC PA decreased its position in shares of Eli Lilly And Co (NYSE:LLY) by 28.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,505 shares of the company’s stock after selling 4,511 shares during the quarter. Berkshire Asset Management LLC PA’s holdings in Eli Lilly And Co were worth $1,235,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Eli Lilly And Co during the second quarter valued at approximately $114,000. Legacy Advisors LLC increased its holdings in shares of Eli Lilly And Co by 118.0% during the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock valued at $116,000 after acquiring an additional 733 shares in the last quarter. Fort L.P. bought a new stake in shares of Eli Lilly And Co during the second quarter valued at approximately $121,000. Financial Management Professionals Inc. bought a new stake in shares of Eli Lilly And Co during the second quarter valued at approximately $128,000. Finally, Twin Tree Management LP increased its holdings in shares of Eli Lilly And Co by 97.9% during the second quarter. Twin Tree Management LP now owns 1,589 shares of the company’s stock valued at $136,000 after acquiring an additional 786 shares in the last quarter. Hedge funds and other institutional investors own 76.56% of the company’s stock.

Several research firms have recently commented on LLY. Credit Suisse Group boosted their price objective on Eli Lilly And Co from $82.00 to $84.00 and gave the company an “underperform” rating in a report on Thursday, June 21st. JPMorgan Chase & Co. set a $123.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Friday, October 5th. Bank of America boosted their price objective on Eli Lilly And Co from $90.00 to $94.00 and gave the company a “neutral” rating in a report on Wednesday, July 25th. Cantor Fitzgerald set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, July 24th. Finally, TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b” rating in a report on Friday, June 29th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Eli Lilly And Co currently has an average rating of “Buy” and a consensus price target of $107.88.

Shares of Eli Lilly And Co stock opened at $110.48 on Friday. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $116.61. The firm has a market cap of $115.25 billion, a P/E ratio of 25.81, a P/E/G ratio of 1.88 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business had revenue of $6.36 billion during the quarter, compared to the consensus estimate of $6.05 billion. During the same quarter in the prior year, the company posted $1.11 earnings per share. Eli Lilly And Co’s revenue was up 9.1% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly And Co will post 5.47 EPS for the current year.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 6,000 shares of the company’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total value of $637,860.00. Following the completion of the transaction, the senior vice president now owns 55,224 shares in the company, valued at approximately $5,870,863.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 185,000 shares of the company’s stock in a transaction on Tuesday, July 24th. The shares were sold at an average price of $92.03, for a total value of $17,025,550.00. Following the completion of the transaction, the insider now owns 121,631,601 shares of the company’s stock, valued at approximately $11,193,756,240.03. The disclosure for this sale can be found here. Insiders have sold 1,785,575 shares of company stock valued at $180,166,130 in the last quarter. 0.11% of the stock is currently owned by corporate insiders.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What do investors mean by earnings per share?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply